Latest Regulatory News

Atlas Arteria confirms the extension of France’s temporary supplemental tax into 2026 but maintains its 40 cents per share distribution guidance, signalling confidence amid regulatory shifts.

Aurora Energy Metals updates investors on its strategic option agreement with Eagle Energy Metals, which is set to become the first US-listed uranium explorer with SMR technology following a pending SPAC merger.

Acadia Pharmaceuticals has received a negative vote from the European Medicines Agency’s committee on its application to market trofinetide for Rett syndrome in the EU, prompting plans for a re-examination request.

Aguia Resources has successfully raised $5 million through a well-supported placement to fund key developments in its Colombian gold and Brazilian phosphate projects. The capital injection aims to boost production and strengthen the company's balance sheet.

Medallion Metals has obtained the crucial environmental green light under the EPBC Act for its Ravensthorpe Gold Project, significantly reducing permitting risks and positioning the company to advance its sulphide production plans.

Noronex Limited has exercised its option to acquire a 51% stake in the Etango North Uranium Project in Namibia, initiating a maiden drilling program backed by AI-driven exploration techniques.

Barton Gold Holdings has kicked off its 2026 drilling campaign at the Tunkillia Gold Project, aiming to secure Ore Reserves, complete a pre-feasibility study, and lodge a Mining Lease application by the end of the year.

Imricor Medical Systems has welcomed Oklahoma Heart Institute as the fourth U.S. site in its pivotal VISABL-AFL clinical trial, accelerating patient recruitment and the FDA approval pathway for its MRI-guided cardiac ablation technology.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.

Aroa Biosurgery’s latest business update reveals promising clinical outcomes from its Myriad trauma study and evolving reimbursement policies that could reshape its market position. The company also projects solid revenue growth for FY26, supported by strategic commercial initiatives.

Rhythm Biosciences has secured a multi-year commercial manufacturing agreement with US-based Quansys Biosciences to produce ColoSTAT® reagent kits, paving the way for broader market rollout of its colorectal cancer diagnostic test.

Resolution Minerals has taken a significant step towards expanding its footprint in the US capital markets by lodging a registration statement with the SEC and launching an ADR facility, while divesting a non-core Alaskan asset to focus on key US projects.